Presented By Praful Ravi at 2016 ASCO Annual Meeting

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

When Using DOPPS Slides. DOPPS Slide Use Guidelines.

Test practice Multiplication. Multiplication 9x2.

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

When Using DOPPS Slides. DOPPS Slide Use Guidelines.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Should We Treat Smoldering Myeloma? YES! Lymphoma Myeloma 2014 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd,

Presented By Raymond Huang at 2014 ASCO Annual Meeting

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

MLRS 242 Immunology Pat Reed Antibodies

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

When Using DOPPS Slides. DOPPS Slide Use Guidelines.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.

Depression As a Predictor of Mortality and Hospitalization Among Hemodialysis Patients in the United States and Europe.

When Using DOPPS Slides. DOPPS Slide Use Guidelines.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.

Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Sham Mailankody at 2016 ASCO Annual Meeting

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

A cura di Filippo de Marinis

Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Highlights: Myeloma Oral Session

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By John Bartlett at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

continued on next slide

Presented By Amrita Krishnan at 2016 ASCO Annual Meeting

New Findings in Hematology: Independent Conference Coverage

Highlights From the 2017 Annual European MS Meeting

A Paradigm Shift in PAH.

continued on next slide

continued on next slide

تحليل الحساسية Sensitive Analysis.

بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية

The Biology Behind BCL2 as a Target in Myeloma

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.

Treating to Target in MS

!'!!. = pt >pt > \ ___,..___,..

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Volume 94, Issue 5, (November 2018)

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Background. Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance.

continued on next slide

Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Andrew Evens at 2016 ASCO Annual Meeting

continued on next slide

Presentation transcript:

Presented By Praful Ravi at 2016 ASCO Annual Meeting Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM) Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Background Presented By Praful Ravi at 2016 ASCO Annual Meeting

High-Risk Smoldering Myeloma Presented By Praful Ravi at 2016 ASCO Annual Meeting

Evolving Pattern in Smoldering Myeloma Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Slide 5 Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Objectives Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Methods Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Methods Presented By Praful Ravi at 2016 ASCO Annual Meeting

Baseline Characteristics Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Evolving Change Presented By Praful Ravi at 2016 ASCO Annual Meeting

Predictors of Early (≤2yrs) Progression Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Slide 12 Presented By Praful Ravi at 2016 ASCO Annual Meeting

Ultra High-Risk Smoldering Myeloma Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Sensitivity Analyses Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Conclusions Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting Acknowledgements Presented By Praful Ravi at 2016 ASCO Annual Meeting